GEN-1 circumvents toxicity issues typically associated with IL-12
IL-12, when administered as a recombinant protein, requires frequent and large bolus administration. This results in significant toxicity. GEN-1 addresses the toxicity issues associated with IL-12. Its nanoparticle profile enables cell transfection followed by persistent, local secretion of IL-12 at therapeutic levels for several days, while avoiding the toxicities associated with recombinant IL-12. Targeted administration directly to the tumor location also helps reduce toxicities because very little IL-12, if any, enters the systemic circulation.
✓ Local administration to improve targeting
✓ Stimulates the body’s immune system to attack cancer
✓ Plasmid vehicle avoids pitfalls of viral vector
✓ Provides persistent increases in IL-12 levels in tumor microenvironment